Codexis (NASDAQ: CDXS) reported Q3 EPS of ($0.29), $0.05 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $12.83 million versus the consensus estimate of $11.49 million.

2024 Financial Guidance Reiterated

Codexis reiterated its full-year 2024 financial guidance originally issued on February 28, 2024, as follows:

Product revenues are expected to be in the range of $38 million to $42 million, excluding revenue related to PAXLOVID™.
R&D revenues are expected to be in the range of $18 million to $22 million.
Gross margin on product revenue is expected to be in the range of 58% to 63%, excluding revenue related to PAXLOVID™.

For earnings history and earnings-related data on Codexis (CDXS) click here.